EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes

Joseph J Carter iD, Nicholas K Hurlburt, Erin M Scherer, Suruchi Singh, Justas V Rodarte, Robin A Smith, Peter Lewis, Rachel Kinzelman, Jacqueline Kieltyka, Madelyn E Cabãn, Gregory C Wipf, Marie Pancera und 1 weitere

PLOS Pathogens · 2025

DOI: 10.1371/journal.ppat.1013086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Joseph J Carter und 12 weiteren Autor:innen. Beteiligte Einrichtung: Fred Hutchinson Cancer Center, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Human papillomavirus 16, Antibodies, Viral, Epitopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies to human papillomavirus (HPV) primarily recognize surface exposed residues on five loops of the major capsid protein (L1) that vary significantly among HPV types. We determined which loops were required for neutralization for 68 HPV16 specific human monoclonal antibodies (mAbs) cloned from participants who received an HPV vaccine and describe molecular features of those antibodies. Chimeric HPV16 pseudovirus (cpsV), each having one surface loop bearing multiple amino acid substitutions, were used to determine neutralization specificity. The HPV16-FG-loop was the loop most frequently required for neutralization (42 of 68, 61.8%), however, all surface loops were required for neutralization by multiple mAbs: HI (13, 19.1%), DE (15, 22.1%), EF (five, 7.4%), BC (four, 5.9%). Antibodies that required multiple loops were common (17, 25.0%). Three mAbs (4.4%) required sequences on the c-terminus of L1 and for another three mAbs the neutralization specificity could not be determined. Two types of mAbs appeared to be overrepresented: ten mAbs used immunoglobin heavy chain variable region 2–70 (IGHV2–70) with immunoglobin light chain variable region 1–40 (IGLV1–40), having characteristic mutations in complementarity determining region two (CDRL2) of the light chain. Cryogenic electron microscopy (Cryo-EM) revealed that two of these antibodies bound five Fabs per capsomer interacting with all five L1-surface loops. The other type of mAbs that appeared to be overrepresented were nine mAbs using IGHV4–34, six of which also used D H 3-16*02 with conserved CDRH3 sequences. Cryo-EM for one of these mAbs, that required the FG-loop for neutralization, was shown to bind one Fab per capsomer at the apex, interacting with the DE- and FG-loops, with sequences of the Fab CDRH3 inserted between the DE- and FG-loops from two L1 proteins. These two types of mAbs were found in the four participants suggesting that these antibodies shared developmental pathways and bound to similar immunodominant epitopes on the virus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalHuman papillomavirus 16Antibodies, ViralEpitopesPapillomavirus InfectionsHumansCapsid ProteinsAntibodies, NeutralizingPapillomavirus VaccinesOncogene Proteins, Viral

Substanzen

Antibodies, MonoclonalAntibodies, ViralEpitopesCapsid ProteinsAntibodies, NeutralizingPapillomavirus VaccinesOncogene Proteins, Viral

Autor:innen und Institutionen

  • Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
  • Human Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
  • Department of Microbiology University of Washington, Seattle, Washington, United States of America.

ORCID-Profile: Joseph J Carter, Denise A Galloway

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
  • National Cancer Institute
  • Fred Hutchinson Cancer Research Center
  • National Institute of General Medical Sciences

Zitieren

APA

Carter, J. J., Hurlburt, N. K., Scherer, E. M., Singh, S., Rodarte, J. V., Smith, R. A., Lewis, P., Kinzelman, R., Kieltyka, J., Cabãn, M. E., Wipf, G. C., Pancera, M., & Galloway, D. A. (2025). Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013086

Vancouver

Carter JJ, Hurlburt NK, Scherer EM, Singh S, Rodarte JV, Smith RA, et al. Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013086

BibTeX
@article{Carter2025,
  author = {Carter, Joseph J and Hurlburt, Nicholas K and Scherer, Erin M and Singh, Suruchi and Rodarte, Justas V and Smith, Robin A and Lewis, Peter and Kinzelman, Rachel and Kieltyka, Jacqueline and Cabãn, Madelyn E and Wipf, Gregory C and Pancera, Marie and Galloway, Denise A},
  title = {Human monoclonal antibodies to HPV16 show evidence for common developmental pathways and public epitopes},
  journal = {PLOS Pathogens},
  year = {2025},
  doi = {10.1371/journal.ppat.1013086}
}
Kostenlos starten →